Immunity to hepatitis B virus (HBV) infection two decades after implementation of universal infant HBV vaccination: association of detectable residual antibodies and response to a single HBV challenge dose
about
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinomaHepatitis B virus and its sexually transmitted infection - an update.The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5-15 y after primary immunization; China, 2009-2010.Sexually transmitted diseases treatment guidelines, 2015.Levels of anti-HBs antibody in HBV-vaccinated students enrolled in the faculty of medicine, dentistry and health professions of a large Italian University.Post-vaccination Immunity Against Hepatitis B Virus and Predictors for Non-responders Among Medical Staff.Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccineResponse to challenge dose among young adults vaccinated for hepatitis B as infants: importance of detectable residual antibody to hepatitis B surface antigen.Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.[Hepatitis B vaccination: a review].Presence of anti-HBs antibodies in blood donors 18-22 years after vaccination and implications for the selection of candidates for plasmapheresis for the production of hyperimmune plasma.Cost-effectiveness of ensuring hepatitis B protection for previously vaccinated healthcare personnel.Hepatitis B vaccination for healthcare personnel in American Samoa: pre-implementation survey for policy decision.Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?Wide dynamic range of surface-plasmon-resonance-based assay for hepatitis B surface antigen antibody optimal detection in comparison with ELISA.
P2860
Q26772324-05B778C2-7666-4E59-A644-ED84994A1989Q30235028-60135A03-2FD9-4F24-82AF-68237EC2425AQ34290738-624F003C-31CD-4007-8165-E020B73A4BAFQ34479272-83DD3BC4-C64C-46B1-AF1E-CED125305306Q34985906-46C7B429-CADB-4D82-876C-78F96356D4AEQ35266912-5D0DBDA4-62CD-4E1C-BB94-A8927761DC10Q35539786-67A995C2-A42C-429B-9559-44379B811B73Q37530082-3A2B5EE3-C847-4F91-B658-5F7703C774F2Q38416873-418C0CF5-F80F-449C-99FC-2550662AB052Q40427997-9420C51C-A689-4C6B-B98A-6DDF9EA8C84AQ41683102-69AFABB5-097A-47DC-81F4-9CDDD0ACA534Q41855000-720DF141-04AC-4A0A-B02E-BE8A9BDA1506Q42211174-B91C008B-5D4F-4708-B7C9-DDA743B100D6Q42240234-6FC07896-3691-4BCE-9562-055425F742A4Q48103063-3DE38518-60AD-4A34-B5F5-55C49B75BDE3Q51456562-D142D666-F66D-4F37-9A51-421AF826110F
P2860
Immunity to hepatitis B virus (HBV) infection two decades after implementation of universal infant HBV vaccination: association of detectable residual antibodies and response to a single HBV challenge dose
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@ast
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@en
type
label
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@ast
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@en
prefLabel
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@ast
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@en
P2093
P2860
P356
P1476
Immunity to hepatitis B virus ...... to a single HBV challenge dose
@en
P2093
Abdirahman Mahamud
Eyasu H Teshale
Jan Drobeniuc
Philip R Spradling
Roxanne Williams
Theresa Dulski
Yolanda Masunu-Faleafaga
P2860
P304
P356
10.1128/CVI.00694-12
P577
2013-02-13T00:00:00Z